Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG.

J Clin Oncol. 1999 Jun;17(6):1939-55. Review.

PMID:
10561236
2.

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group.

J Clin Oncol. 2002 Aug 1;20(15):3328-43. Review.

PMID:
12149307
3.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.

J Clin Oncol. 2002 Aug 1;20(15):3317-27. Review.

PMID:
12149306
4.

Overview of the main outcomes in breast-cancer prevention trials.

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P.

Lancet. 2003 Jan 25;361(9354):296-300. Review.

PMID:
12559863
5.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

6.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947
7.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

8.

Future possibilities in the prevention of breast cancer: breast cancer prevention trials.

Cuzick J.

Breast Cancer Res. 2000;2(4):258-63. Epub 2000 May 19. Review.

9.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
10.

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.

Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM.

J Clin Oncol. 2013 Aug 10;31(23):2942-62. doi: 10.1200/JCO.2013.49.3122. Epub 2013 Jul 8. Review. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.

PMID:
23835710
11.

Breast cancer chemoprevention.

Mamounas EP.

Hematol Oncol Clin North Am. 2000 Jun;14(3):727-38. Review. No abstract available.

PMID:
11203331
12.

Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.

Nelson HD, Smith ME, Griffin JC, Fu R.

Ann Intern Med. 2013 Apr 16;158(8):604-14. doi: 10.7326/0003-4819-158-8-201304160-00005. Review.

PMID:
23588749
13.

Chemoprevention or mastectomy for women at high risk of developing breast cancer.

Sismondi P, D'Alonzo M, Pecchio S, Bounous VE, Robba E, Biglia N.

Maturitas. 2015 Nov;82(3):271-3. doi: 10.1016/j.maturitas.2015.07.002. Epub 2015 Jul 26. Review.

PMID:
26276104
14.

The selective estrogen receptor modulators in breast cancer prevention.

Li F, Dou J, Wei L, Li S, Liu J.

Cancer Chemother Pharmacol. 2016 May;77(5):895-903. doi: 10.1007/s00280-016-2959-0. Epub 2016 Jan 20. Review.

PMID:
26787504
15.

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.

Jordan VC, Gapstur S, Morrow M.

J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57. Review.

PMID:
11584060
16.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

Oncologist. 2004;9(2):116-25. Review.

17.

Development of a new prevention maintenance therapy for postmenopausal women.

Jordan VC.

Recent Results Cancer Res. 1999;151:96-109. Review.

PMID:
10337721
18.

Update on breast cancer prevention.

Rastogi P, Vogel VG.

Oncology (Williston Park). 2003 Jun;17(6):799-805; discussion 808-10, 813. Review.

19.

Safety and efficacy of antiestrogens for prevention of breast cancer.

Reddy P, Chow MS.

Am J Health Syst Pharm. 2000 Jul 15;57(14):1315-22; quiz 1323-5. Review.

PMID:
10918921
20.

Breast cancer prevention trials.

Rhodes DJ, Hartmann LC, Perez EA.

Curr Oncol Rep. 2000 Nov;2(6):558-65. Review.

PMID:
11122893

Supplemental Content

Support Center